Condition
Multi-Drug Resistant Nephrotic Syndrome clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Multi-Drug Resistant Nephrotic Syndrome clinical trials that are recruiting, in China. By phase: Early Phase 1 (3), Phase 1 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1Country
Newest Multi-Drug Resistant Nephrotic Syndrome clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| CD19/BCMA UCART for B cell–related autoimmune diseases | Early Phase 1 | Hangzhou, Zhejiang | Recruiting | May 14, 2026 |
| Allogeneic CD19/BCMA CAR‑T for B‑cell autoimmune disease | Early Phase 1 | Hangzhou, Zhejiang | Recruiting | Apr 2, 2026 |
| Allogeneic CAR T cells targeting CD19 and BCMA for B‑cell autoimmune diseases | Phase 1 | Hangzhou, Zhejiang | Recruiting | Dec 26, 2025 |
| Using CAR-NK cells to treat autoimmune diseases like lupus and nephrotic syndrome | Early Phase 1 | Hangzhou, Zhejiang | Recruiting | Jan 27, 2025 |
| CAR-T cell therapy for treating multi-drug resistant nephrotic syndrome | Phase 1 | Hangzhou, Zhejiang | Recruiting | Aug 14, 2024 |
All recruiting trials (5)
-
CD19/BCMA UCART for B cell–related autoimmune diseases
This early-stage study tests QT-219CX, a universal allogeneic CAR-T cell therapy that targets CD19 and BCMA, in people with refractory B-cell–related autoimmune diseases to see if it can be given safely and provide early signs of benefit.
-
Allogeneic CD19/BCMA CAR‑T for B‑cell autoimmune disease
This Phase 1 study will test a donor-derived CAR‑T therapy that targets CD19 and BCMA to try to reset the immune system in people with refractory B‑cell autoimmune diseases such as SLE, IgA nephropathy, systemic sclerosis, and resistant nephrotic syndrome.
-
Allogeneic CAR T cells targeting CD19 and BCMA for B‑cell autoimmune diseases
This study will try a single infusion of off‑the‑shelf CAR T cells that target CD19 and BCMA to treat people with B‑cell–mediated autoimmune diseases such as lupus, IgA nephropathy, and drug‑resistant nephrotic syndrome.
-
Using CAR-NK cells to treat autoimmune diseases like lupus and nephrotic syndrome
This study is testing a new treatment using CAR-NK cells to see if it can help people with autoimmune diseases like lupus and nephrotic syndrome feel better.
-
CAR-T cell therapy for treating multi-drug resistant nephrotic syndrome
This study is testing a new CAR-T cell therapy to see if it can help children and adults with hard-to-treat nephrotic syndrome feel better and avoid kidney failure.
Related topics
Quick answers
How many Multi-Drug Resistant Nephrotic Syndrome clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Early Phase 1: 3, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.